HB301qc (HB233): Case Studies in Human Biology and Translational Medicine (January G1 Year)

HB301qc (HB233): Case Studies in Human Biology and Translational Medicine (January G1 Year)

Preregister for HB301qc (HB233) by filling out the form below.

Enrollment in HB301qc is required for, and restricted to, students in the Leder Human Biology and Translational Medicine program. LHB students enroll in HBTM 301qc during January of the G1 year, and receive credit for a quarter-course upon satisfactory completion of the course, which includes mandatory attendance. The course is led by editors of the New England Journal of Medicine in collaboration with investigators from industry and academia. The course meets every weekday morning for 60-90 minutes per day during 2 weeks in January, and the curriculum is designed to allow students to perform a lab rotation concurrently with HBTM 301qc.  Course meetings include lecture and small-group discussion formats, and all course meetings are held at the NEJM editorial offices, on the 6th floor of the Countway Library at HMS.  

Each week of the course focuses on a different case study in translational medicine. These case studies highlight examples of fundamental discoveries in human disease biology that provided new insights into the diagnosis, prevention, and treatment of human disease, and led to development of new therapeutic approaches. Through the process of reviewing these case studies and critically reading selected papers, students will gain familiarity with research methods in human biology and also learn about fundamentals of clinical trial design and experimental design, clinical epidemiology, and biostatistics. In the first week, Dr. Mark Goldberg will describe the research establishing the molecular defect causing Fabry Disease (alpha-galactosidase A deficiency), and the development and clinical testing of effective treatment of the disease with alpha-galactosidase beta. In the second week, Dr. Jeffrey Drazen will review how basic discoveries in the enzymology of leukotrienes led to the development of new therapeutic agents used to treat asthma. Course directors Drs. Caren Solomon and Mary Beth Hamel (associate editors at NEJM) will introduce cohort studies and randomized control studies. Thus, HBTM301qc provides students with essential background for obtaining the statistical power of experimental observations in both basic and clinical investigations, assessing the outcomes of novel therapies, and dissecting the complexities of genetic and environmental effects.

Curriculum Fellow: Chris Burtner Christopher_Burtner@hms.harvard.edu

Course Dates for 2018: January 8 - January 19; M - Th 9:00am - 10:30am; F 9:00am - 10:00am

No class on Monday, January 15, in recognition of Martin Luther King.